metformin has been researched along with sorafenib in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 9 (34.62) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brockmöller, J; Tzvetkov, MV | 1 |
| Bernards, R; Groenendijk, FH; Hauptmann, M; Horlings, HM; Jonkers, J; Mellema, WW; Schut, E; Smit, EF; van den Heuvel, MM; van der Burg, E; Willems, SM | 1 |
| Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF | 1 |
| Chen, G; Derwahl, M; Nicula, D; Renko, K | 1 |
| Chen, T; Cheng, X; Jia, Y; Jiang, T; Li, J; Liu, T; Liu, Z; Wang, F; Zeng, J; Zhang, C; Zhang, L; Zhu, H | 1 |
| Brunetti, O; Casadei Gardini, A; Cascinu, S; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Masi, G; Nanni, O; Ricca Rosellini, S; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Tamburini, E; Tenti, E; Ulivi, P; Vivaldi, C | 1 |
| Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X | 1 |
| Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B | 1 |
| Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F | 1 |
| Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U | 1 |
| Antoniewicz, MR; Au, J; DeWaal, D; Guzman, G; Hay, N; Jeon, SM; Long, CP; Nogueira, V; Patra, KC; Terry, AR | 1 |
| Feng, Y; Guo, X; Huang, X; Li, X; Luo, X; Wu, M; Wu, S | 1 |
| Hinrichs, JB; Ivanyi, P; Kirstein, MM; Koch, S; Manns, MP; Marhenke, S; Pinter, M; Rodt, T; Scheiner, B; Schulte, L; Schweitzer, N; Vogel, A; Voigtländer, T; Weinmann, A | 1 |
| Gao, ZH; Guo, XC; Ji, M; Li, L; Wang, QQ | 1 |
| Bort, A; de Miguel, I; Diaz-Laviada, I; Mateos-Gómez, PA; Sánchez, BG | 1 |
| abuTaleb, F; Ebian, H; El Shorbagy, S; Elbana, KA; Haggag, R; Harb, OA; Labib, HA; Mohammed, MS; Rashied, HA | 1 |
| Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K | 1 |
| Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY | 1 |
| Bardin, C; Blanchet, B; Desbois-Mouthon, C; Hamoudi, RA; Harati, R; Praz, F; Vandamme, M | 1 |
| Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S | 1 |
| Kuppusamy, P; Nagalingam, A; Saxena, NK; Sharma, D; Siddharth, S; Wu, Q | 1 |
| Dong, Y; Gao, Y; Hu, Z; Jiang, J; Li, L; Li, W; Mang, Y; Ran, J; Yang, C; Zhang, S; Zhao, Y; Zhu, J | 1 |
2 review(s) available for metformin and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Activators; Female; Humans; Metformin; Phosphorylation; Signal Transduction; Sorafenib; Treatment Outcome | 2020 |
3 trial(s) available for metformin and sorafenib
| Article | Year |
|---|---|
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Female; Humans; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Egypt; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Sorafenib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
21 other study(ies) available for metformin and sorafenib
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Polymorphic OCT1: a valid biomarker, but for which drugs?
Topics: Biomarkers, Pharmacological; Cations; Humans; Metformin; Morphine; Niacinamide; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Sorafenib | 2013 |
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Metformin; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Urokinase-Type Plasminogen Activator | 2014 |
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Metformin; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Sorafenib; Spheroids, Cellular; Thyroid Neoplasms; Tumor Stem Cell Assay | 2015 |
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Metformin; Microtubule-Associated Proteins; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sorafenib; Tandem Repeat Sequences; TOR Serine-Threonine Kinases | 2015 |
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Metformin; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thioredoxins; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Metformin; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metformin; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sirtuin 3; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; Hexokinase; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Metabolic Flux Analysis; Metformin; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Metformin reverses stem cell‑like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial‑mesenchymal transformation.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Neoplastic Stem Cells; Sorafenib | 2018 |
Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Germany; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Prognosis; Propensity Score; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis | 2019 |
Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Drug Synergism; Endometrial Hyperplasia; Female; Metformin; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawley; Sorafenib | 2020 |
Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation; Hep G2 Cells; Humans; Lipid Metabolism; Lipogenesis; Liver Neoplasms; Metformin; Neoplastic Stem Cells; Phosphorylation; Sorafenib | 2020 |
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Taiwan | 2020 |
Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diabetes Mellitus; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Hep G2 Cells; Humans; Liver Neoplasms; Metformin; Mice; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Neoplasms; Metformin; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Liver Neoplasms; Metformin; Mice; Sorafenib | 2023 |